On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his ...

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best performing pharma stocks in 2025. On January 7, Truist raised ...

For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other developed countries. Branded medicines carry even steeper premiums.

X4 Pharmaceuticals (XFOR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of ...

The biotechnology sector offers investors a high-risk, high-reward opportunity as companies race to bring breakthrough ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 6: Rigel ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Emcure Pharmaceuticals has witnessed a strong bullish breakout from its consolidation phase, supported by a clear surge in ...

Shares of Evoke Pharma more than doubled after the developer of biotech treatments for gastrointestinal and rare diseases agreed to a buyout from closely held rival QOL Medical for a substantial ...

The New Year's Champagne turned flat for Madrigal Pharmaceuticals (NASDAQ: MDGL) on Tuesday. Investors traded out of the ...

Since 2020, four directors of Square Pharmaceuticals have collectively bought about 1.51 crore shares of the company, investing close to Tk300 crore ...

According to a disclosure, the shares will be purchased at the prevailing market price either in the public or block market within the next 30 working days.